Inventiva (NASDAQ:IVA) Shares Gap Up – Here’s Why

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) gapped up before the market opened on Monday . The stock had previously closed at $5.78, but opened at $6.16. Inventiva shares last traded at $6.0310, with a volume of 55,226 shares changing hands.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. UBS Group began coverage on Inventiva in a report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a report on Thursday, January 22nd. Leerink Partners started coverage on Inventiva in a research report on Monday, January 12th. They issued an “outperform” rating and a $12.00 price target for the company. Barclays assumed coverage on Inventiva in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 price objective on the stock. Finally, Truist Financial initiated coverage on Inventiva in a research note on Thursday. They set a “buy” rating and a $13.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $16.56.

Inventiva Stock Performance

The firm has a 50-day moving average of $6.30 and a 200-day moving average of $5.36.

Institutional Investors Weigh In On Inventiva

Several institutional investors and hedge funds have recently modified their holdings of IVA. Alyeska Investment Group L.P. purchased a new position in Inventiva during the fourth quarter valued at $2,325,000. Squadron Capital Management LLC purchased a new stake in Inventiva in the 4th quarter worth $1,395,000. Marshall Wace LLP purchased a new stake in Inventiva in the 4th quarter worth $800,000. Superstring Capital Management LP bought a new position in shares of Inventiva during the 4th quarter valued at about $465,000. Finally, Quadrature Capital Ltd bought a new position in shares of Inventiva during the 4th quarter valued at about $311,000. Institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.